Abstract
Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to either rivaroxaban 10 mg (R10, n=37), rivaroxaban 15 mg (R15, n=35), or DAPT with aspirin 75 mg and clopidogrel 75 mg (n=33). The primary end point was thrombin generation (prothrombin fragments 1+2) measured 2 to 4 hours after drug intake, 10 days after treatment initiation. Thrombin-antithrombin complex, D-dimers, rivaroxaban concentrations were also measured at 10 days and 3 months. Clinical end points were evaluated at 3-month follow-up. The primary end point was reduced with R10 (179 pmol/L [interquartile range (IQR), 129-273], P<0.0001) and R15 (163 pmol/L [IQR,...Continue Reading
References
Jan 1, 1993·Cardiology·S A MousaT M Reilly
Jun 15, 1996·Circulation·L M BiasucciA Maseri
Mar 21, 1998·Journal of the American College of Cardiology·C B GrangerE G Bovill
May 20, 1999·Journal of the American College of Cardiology·Y H LiJ H Chen
Apr 3, 2002·Thrombosis Research·Polona PeternelMojca Stegnar
Jul 5, 2003·Blood·Diego ArdissinoPier Mannuccio Mannucci
Jul 9, 2004·JAMA : the Journal of the American Medical Association·John L PetersenRobert M Califf
Oct 4, 2005·Clinical Pharmacology and Therapeutics·Dagmar KubitzaGeorg Wensing
Jun 13, 2006·Lancet·UNKNOWN ACTIVE Writing Group of the ACTIVE InvestigatorsS Yusuf
Jun 2, 2011·Platelets·Marek KozinskiJacek Kubica
May 15, 2013·Journal of the American College of Cardiology·Marina UrenaRéda Ibrahim
Jul 3, 2013·Thrombosis Journal·Wolfgang MueckJan Stampfuss
Sep 12, 2014·Thrombosis and Haemostasis·T N BontenJ G van der Bom
Jun 20, 2015·Journal of the American College of Cardiology·David R HolmesVivek Y Reddy
Jan 30, 2016·European Heart Journal·Lucas V A BoersmaUNKNOWN EWOLUTION investigators
Jun 16, 2016·Stroke; a Journal of Cerebral Circulation·Rafal MeusAnetta Undas
Oct 21, 2016·Thrombosis Research·Joji HagiiKen Okumura
Jan 20, 2017·Thrombosis and Haemostasis·Uwe ZeymerDietmar Trenk
Aug 15, 2017·EuroIntervention : Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·Paul GuedeneyGilles Montalescot
Sep 10, 2017·British Journal of Clinical Pharmacology·Shigeo HorinakaToshihiko Ishimitsu
Apr 7, 2018·Journal of the American College of Cardiology·Laurent FauchierPascal Defaye
May 13, 2018·Circulation·Srinivas R DukkipatiVivek Y Reddy
Aug 26, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Johanne SilvainUNKNOWN ATOLL Investigators
Jun 7, 2019·JACC. Cardiovascular Interventions·Lars SøndergaardDavid R Holmes
Jun 20, 2019·Journal of Thrombosis and Haemostasis : JTH·Virginie SiguretIsabelle Gouin-Thibault
Citations
Jul 18, 2020·Circulation. Cardiovascular Interventions·Derek S Chew, Jonathan P Piccini
May 1, 2021·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Shiv BaggaSarju Ganatra
Jun 1, 2021·Seminars in Thrombosis and Hemostasis·Omayra C D LiesdekRoger E G Schutgens
Jul 6, 2021·Frontiers in Pharmacology·Xiaoye LiQianzhou Lv
Jul 5, 2021·JACC. Clinical Electrophysiology·Domenico G Della RoccaAndrea Natale
Oct 5, 2021·Frontiers in Pharmacology·Xiaoye LiJunbo Ge